SCHEMBL3525492

SCHEMBL3525492

COC(=O)CCc1cc2cc(C(C)=O)ccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 4/20 0.50
▸ MTNR1B P49286 3/20 0.50
▸ HRH4 Q9H3N8 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ PLD2 O14939 1/20 0.41
▸ PLD1 Q13393 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ EGFR P00533 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HRH3 Q9Y5N1 2/20 0.39
▸ MMP2 P08253 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ LOXL2 Q9Y4K0 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525164 0.85 CYP1A2 (0.46) MTNR1AMTNR1BSMN1; SMN2KDM4EALDH1A1
SCHEMBL852679 0.83 BACE1 (0.49) MTNR1AMTNR1BHRH4SMN1; SMN2KDM4E
SCHEMBL22074027 0.82 MTNR1A (0.68) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL3525308 0.82 MTNR1A (0.48) MTNR1AMTNR1BHRH4SMN1; SMN2KDM4E
SCHEMBL3525255 0.82 EGFR (0.54) MTNR1AMTNR1BHRH4SMN1; SMN2MAPT
SCHEMBL9108723 0.80 MTNR1A (0.61) MTNR1AMTNR1BHRH4SMN1; SMN2KDM4E
SCHEMBL3528754 0.79 MTNR1A (0.45) MTNR1AMTNR1BSMN1; SMN2KDM4EALDH1A1
SCHEMBL3529064 0.79 HRH4 (0.46) MTNR1AMTNR1BHRH4SMN1; SMN2PLD2
SCHEMBL14117470 0.79 MTNR1A (0.48) MTNR1AMTNR1BHRH4PLD2PLD1
SCHEMBL7473980 0.78 MTNR1A (0.47) MTNR1AMTNR1BSMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 — — US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 — — US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 — — US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP MTNR1A 301/4885MTNR1B 164/4885HRH4 1483/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG MTNR1A 22/4885MTNR1B 25/4885HRH4 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback